Company adjusts outlook for 2024 market performance.
bioAffinity Technologies downgrades its guidance for 2024 due to market dynamics, focusing on strategic priorities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day